JAK2 and breast cancer: Pembrolizumab + a JAK2 inhibitor Ruxolitinib in TNBC (NCT03012230) + a CDK4/6 inhibitor Abemaciclib in HR + /HER2- BC (NCT02779751) + Trastuzumab in HER2 + BC (NCT02318901) + PARP inhibitor Niraparib in TNBC (NCT02657889)